Safety and Performance of a Synthetic Tissue Sealant in Reducing Fluid Leakage in Hepatobiliary and Pancreatic Surgery

NCT04024956 | Completed

• 1 other identifier: CIP-3
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 2

Brief Summary

Polyganics BV (Groningen, The Netherlands), in close collaboration with University Hospital-Eppendorf (UKE) Hamburg, has developed the Sealing Device for use in hepato-pancreato-bilary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site. The Sealing Device has been challenged in pre-clinical testing (laboratory and in-vivo work), but has not been evaluated for safety and performance in humans. This investigation will be conducted to clinically assess the safety and performance of Sealing Device as a means to reduce bile and pancreatic juice leakage in hepato-pancreato-bilary (HPB) surgery. Secondarily, the control of minimal to moderate bleeding will be assessed. To achieve adequate representation of the primary objective, the study will contain two separate surgical patient groups: Liver and Pancreas. The primary objective of the study is to demonstrate safety and performance in reducing intra- and post-operative leakage (bile and pancreatic juices) by using the Sealing Device in patients undergoing elective hepatic resection or distal pancreatectomy. The study will be conducted as an open-label, single-arm, multicenter study with a 16 months follow up. Up to 80 patients (40 liver and 40 pancreas patients) will be enrolled at up to 7 sites in Europe.

Conditions

Pancreatectomy; Hepatic Resection

Keywords

Hepatic resection; Distal pancreatectomy; Sealant

Outcome Measures

Primary Outcomes (2)

• Bile leakage

  Incidence of post-operative bile leakage (International Study Group of Liver Surgery Bile leakage Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C

  30 days

• Pancreatic leakage

  Incidence of post-operative pancreatic juice leakage (International Study Group of Pancreas Surgery Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C

  30 days

Secondary Outcomes (11)

• Bleeding

  Day 1

• Leak-associated comorbidities

  16 months

• re-intervention

  16 months

• Ease of Use

  Day 1

• Post-operative bile leakage

  90 and 180 days

Study Arms (1)

Sealing Device

EXPERIMENTAL

Sealing Device applied in hepatic resection or distal pancreatectomy

Device: Sealing Device

Interventions

Sealing Device DEVICE

The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.

Sealing Device

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects will be eligible according the following criteria:
• Subjects who are able to provide a written informed consent prior to participating in the clinical investigation.
• Subjects who are ≥ 18 years old.
• Subjects who are able to comply with the follow-up or other requirements.
• Subjects who are planned for an elective hepatic resection or distal pancreatectomy.
• During the surgery, the patients also need to comply with the intraoperative criteria.
• Subjects will be eligible according the following criteria:
• \. Patch is applied manually (during open procedure, conversion procedure, or laparoscopic assisted procedure).

You may not qualify if:

• Subjects who meet any of the following criteria will be excluded from participation:
• Female subjects who are pregnant and/or breastfeeding.
• Subjects with a known allergy to any of the components of the Sealing Device (Polyurethane (SDPU), 8-ArmPEG40k-SC (SDA), Disodium Hydrogen Phosphate (Na2HPO4) (BS) and DC-Green #6 (SDD)).
• Subject with bleeding disorders requiring anti-coagulation medication (except acetylsalicylic acid).
• Subjects who receive double-coagulation.
• Subjects who receive peritoneal dialysis.
• Subjects who previously required liver transplantation.
• Subjects with a presence of systemic infection.
• Subject who previously participated in this study, or in any investigational drug- or device study within 30 days of screening.
• Subjects undergoing a procedure requiring an anastomosis (e.g. Klatskin tumours or Whipple).
• Subjects who meet any of the following criteria will be excluded from participation:
• Subjects with multivisceral resections, except resection of spleen.
• Not able to apply the patch(es) according to the Instructions For Use.
• Total surgery requiring \> 3 HPB Sealing Devices of 10 x 5 cm (which equals a resection surface of more than 88cm2).
• Additional for liver group:

Sponsors & Collaborators

• Polyganics BV: lead
• Genae: collaborator

Study Sites (2)

Universitats Klinikum Hamburg-Eppendorf

Hamburg, Germany

Location

University Hospital Oldenburg

Oldenburg, Germany

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Open-label, single-arm, multicenter study

Study Record Dates

• First Submitted: July 16, 2019
• First Posted: July 18, 2019
• Study Start: August 25, 2020
• Primary Completion: November 19, 2021
• Study Completion: May 26, 2023
• Last Updated: July 3, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will not share

Locations

DE (2)